0.828
전일 마감가:
$0.83
열려 있는:
$0.83
하루 거래량:
155.93K
Relative Volume:
0.03
시가총액:
$3.02M
수익:
-
순이익/손실:
$-11.38M
주가수익비율:
-0.0299
EPS:
-27.73
순현금흐름:
$-12.72M
1주 성능:
-2.84%
1개월 성능:
-26.73%
6개월 성능:
+74.28%
1년 성능:
-80.74%
Windtree Therapeutics Inc Stock (WINT) Company Profile
명칭
Windtree Therapeutics Inc
전화
(215) 488-9300
주소
2600 KELLY ROAD, WARRINGTON, PA
WINT을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
WINT
Windtree Therapeutics Inc
|
0.828 | 3.03M | 0 | -11.38M | -12.72M | -27.73 |
![]()
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Windtree Therapeutics Inc Stock (WINT) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2020-06-26 | 개시 | Ladenburg Thalmann | Buy |
Windtree Therapeutics Inc 주식(WINT)의 최신 뉴스
Windtree Therapeutics Inc. Reports Q1 2025 Financial Results - TipRanks
Windtree Therapeutics (WINT) Registers Up to 42.17M Shares for R - GuruFocus
Windtree Therapeutics (WINT) Plans to Sell Over 42 Million Shares | WINT Stock News - GuruFocus
Windtree Therapeutics Unveils U.S. Exclusivity Strategy for Istaroxime - MSN
Windtree (WINT) Sets Ambitious Plans for Revenue Growth and Rese - GuruFocus
Windtree Therapeutics Reports First Quarter 2025 Financial Resul - GuruFocus
Windtree Therapeutics Reports First Quarter 2025 Financial Results and Provides Key Business Updates | WINT Stock News - GuruFocus
Windtree Therapeutics Transforms Business Model: New Revenue Strategy, Real Estate Deal, and Clinical Progress - Stock Titan
WINDTREE THERAPEUTICS INC /DE/ SEC 10-Q Report - TradingView
Windtree Therapeutics (WINT) to Release Earnings on Wednesday - Defense World
WINT: Windtree Therapeutics Reveals Promising Data on Istaroxime - GuruFocus
Windtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025 - The Manila Times
Windtree Therapeutics Announces Positive Results on Istaroxime and SERCA2a Activator in Reducing Arrhythmias at ESC Heart Failure Congress - Nasdaq
Windtree Therapeutics Announces Plans to Acquire Multifamily Residential Property - MSN
Warrington-Based Windtree Therapeutics Buys Huston Apartment Complex - BUCKSCO.Today
Daily Progress: Windtree Therapeutics Inc (WINT) Drop -11.76, Closing at 0.90 - DWinneX
Windtree Therapeutics Secures Patent in Japan for Cancer Treatment Platform - MSN
Windtree Therapeutics (WINT) Eyes U.S. Exclusivity for Istaroxime | WINT Stock News - GuruFocus
Windtree Announces Istaroxime Exclusivity and Intellectual Prope - GuruFocus
Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US - The Manila Times
Windtree Therapeutics Announces Strategic Pathway for 7.5 Years of U.S. Exclusivity for Istaroxime in Cardiogenic Shock - Nasdaq
Windtree Secures 7.5-Year Exclusivity Strategy for Revolutionary Cardiogenic Shock Treatment - Stock Titan
Why biotech firm Windtree Therapeutics is buying a 436-unit apartment complex - The Business Journals
WINT’s Stock Market Adventure: -94.27% YTD Growth Amidst Volatility - investchronicle.com
Examining Windtree Therapeutics Inc (WINT) more closely is necessary - uspostnews.com
Market Resilience: Windtree Therapeutics Inc (WINT) Finishes Weak at 1.00, Down -14.53 - DWinneX
Windtree Therapeutics (WINT) Pursues Strategic Real Estate Acqui - GuruFocus
Windtree Therapeutics (WINT) Pursues Strategic Real Estate Acquisition | WINT Stock News - GuruFocus
Windtree Therapeutics Raises $2.5M in Private Placement - TipRanks
Windtree Announces Strategic Transaction to Drive Revenue Generation in Support of Ongoing Therapeutic Pipeline Development - The Manila Times
Windtree Therapeutics Reports 2024 Financial Results and Strategic Developments - MSN
Windtree Therapeutics announces board member resignation By Investing.com - Investing.com Nigeria
Windtree Therapeutics announces board member resignation - Investing.com Australia
Windtree Therapeutics (WINT) Advances Clinical and Strategic Ini - GuruFocus
Windtree Therapeutics Reports 2024 Progress and Strategy Shift - TipRanks
WINDTREE THERAPEUTICS INC /DE/ SEC 10-K Report - TradingView
Windtree Therapeutics reports FY24 EPS ($104.35) vs. ($4,718.84) last year - TipRanks
Windtree Therapeutics sees cash runway through April - TipRanks
Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates - TradingView
Company Secures Additional Funding to Sustain Operations Through April 2025 | WINT Stock News - GuruFocus
Windtree Slashes Losses by $18.5M as Cardiogenic Shock Drug Shows Promise - Stock Titan
Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Significant Growth in Short Interest - Defense World
Windtree Therapeutics Issues Convertible Notes to Raise $250,000 - Investing.com Australia
Windtree Therapeutics (WINT) to Release Earnings on Tuesday - Defense World
Evofem Biosciences Inks Amendment with Windtree for PHEXXI Supply - Investing.com
Windtree Therapeutics Delays Annual Report Filing - TipRanks
Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Large Decline in Short Interest - Defense World
Windtree Therapeutics Regains Nasdaq Compliance - MSN
Windtree Therapeutics Announces Reverse Stock Split to Maintain Nasdaq Compliance - MSN
Windtree Therapeutics Inc (WINT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):